Search research articles
Contact Us
Filters
Showing results (31-40 of 210) with videos related to
Page
of 21
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 18, 2019
Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications
Biagio Ricciuti, Suzanne E Dahlberg, Anika Adeni, et al.
Cancer Immunology Research
|
April 7, 2018
Sarcoid-Like Granulomatosis of the Lung Related to Immune-Checkpoint Inhibitors: Distinct Clinical and Imaging Features of a Unique Immune-Related Adverse Event
Mizuki Nishino, Lynette M Sholl, Mark M Awad, et al.
Lung Cancer (Amsterdam, Netherlands)
|
July 1, 2025
Acquired SMARCA4 alterations: An uncommon contributor to cancer progression in lung adenocarcinomas
Andréanne Gagné, Joao Victor M Alessi, Biagio Ricciuti, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
May 31, 2017
Diabetic Ketoacidosis as an Immune-related Adverse Event from Pembrolizumab in Non-Small Cell Lung Cancer
Giulia C Leonardi, Geoffrey R Oxnard, Andrea Haas, et al.
JCO Precision Oncology
|
January 20, 2022
Meta-Analysis of PD-L1 Expression As a Predictor of Survival After Checkpoint Blockade
Andrea Arfè, Geoffrey Fell, Brian Alexander, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 23, 2025
The Genomic Landscape of NSCLC in Systemic Sclerosis Reveals Frequent TP53 Mutations and a Paucity of Actionable Oncogenes
Igor Odintsov, Mark M Hammer, Biagio Ricciuti, et al.
Journal of Thoracic Imaging
|
April 16, 2019
Tumor Volume Analysis as a Predictive Marker for Prolonged Survival in Anaplastic Lymphoma Kinase-rearranged Advanced Non-Small Cell Lung Cancer Patients Treated With Crizotinib
Tomoyuki Hida, Suzanne E Dahlberg, Christine A Lydon, et al.
The Oncologist
|
April 12, 2021
Prevalence and Tolerance of Prognostic Uncertainty Among Thoracic Oncologists
Anand R Habib, Richard Chen, Emily S Magnavita, et al.
Abdominal Radiology (New York)
|
February 22, 2019
Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor
Francesco Alessandrino, Sonia Sahu, Mizuki Nishino, et al.
Cancer Immunology Research
|
November 22, 2015
Radiologic Heterogeneity in Responses to Anti-PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma
Guillermo de Velasco, Katherine M Krajewski, Laurence Albiges, et al.
Page
of 21
Search research articles
Search
Showing results (31-40 of 210) with videos related to
Sort By:
Page
of 21
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 18, 2019
Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications
Biagio Ricciuti, Suzanne E Dahlberg, Anika Adeni, et al.
Cancer Immunology Research
|
April 7, 2018
Sarcoid-Like Granulomatosis of the Lung Related to Immune-Checkpoint Inhibitors: Distinct Clinical and Imaging Features of a Unique Immune-Related Adverse Event
Mizuki Nishino, Lynette M Sholl, Mark M Awad, et al.
Lung Cancer (Amsterdam, Netherlands)
|
July 1, 2025
Acquired SMARCA4 alterations: An uncommon contributor to cancer progression in lung adenocarcinomas
Andréanne Gagné, Joao Victor M Alessi, Biagio Ricciuti, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
May 31, 2017
Diabetic Ketoacidosis as an Immune-related Adverse Event from Pembrolizumab in Non-Small Cell Lung Cancer
Giulia C Leonardi, Geoffrey R Oxnard, Andrea Haas, et al.
JCO Precision Oncology
|
January 20, 2022
Meta-Analysis of PD-L1 Expression As a Predictor of Survival After Checkpoint Blockade
Andrea Arfè, Geoffrey Fell, Brian Alexander, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 23, 2025
The Genomic Landscape of NSCLC in Systemic Sclerosis Reveals Frequent TP53 Mutations and a Paucity of Actionable Oncogenes
Igor Odintsov, Mark M Hammer, Biagio Ricciuti, et al.
Journal of Thoracic Imaging
|
April 16, 2019
Tumor Volume Analysis as a Predictive Marker for Prolonged Survival in Anaplastic Lymphoma Kinase-rearranged Advanced Non-Small Cell Lung Cancer Patients Treated With Crizotinib
Tomoyuki Hida, Suzanne E Dahlberg, Christine A Lydon, et al.
The Oncologist
|
April 12, 2021
Prevalence and Tolerance of Prognostic Uncertainty Among Thoracic Oncologists
Anand R Habib, Richard Chen, Emily S Magnavita, et al.
Abdominal Radiology (New York)
|
February 22, 2019
Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor
Francesco Alessandrino, Sonia Sahu, Mizuki Nishino, et al.
Cancer Immunology Research
|
November 22, 2015
Radiologic Heterogeneity in Responses to Anti-PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma
Guillermo de Velasco, Katherine M Krajewski, Laurence Albiges, et al.
Page
of 21